(Q37984567)

26 August 2017

Clinical pharmacokinetics and pharmacodynamics of vildagliptin (English)

1 reference

26 August 2017

1 reference

1 reference

Yan-Ling He

1

1 reference

26 August 2017

1 March 2012

1 reference

Clinical Pharmacokinetics

26 August 2017

1 reference

26 August 2017

51

1 reference

26 August 2017

147-162

1 reference

26 August 2017

3

1 reference

https://scigraph.springernature.com/pub.10.2165/11598080-000000000-00000

26 August 2017

0 references

cites work

Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes

1 reference

https://api.crossref.org/works/10.2165%2F11598080-000000000-00000

Glucagon-like peptide-1 (7-36)amide and glucose-dependent insulinotropic polypeptide secretion in response to nutrient ingestion in man: acute post-prandial and 24-h secretion patterns.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11598080-000000000-00000

Glucagon-like peptide-1 7-36: a physiological incretin in man.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11598080-000000000-00000

Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide-1-(7-36) amide infused at near-physiological insulinotropic hormone and glucose concentrations

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11598080-000000000-00000

Influence of glucagon-like peptide 1 on fasting glycemia in type 2 diabetic patients treated with insulin after sulfonylurea secondary failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11598080-000000000-00000

Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11598080-000000000-00000

What do we know about the secretion and degradation of incretin hormones?

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11598080-000000000-00000

Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11598080-000000000-00000

Therapy of type 2 diabetes mellitus based on the actions of glucagon-like peptide-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11598080-000000000-00000

Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11598080-000000000-00000

Circulation and degradation of GIP and GLP-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11598080-000000000-00000

Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11598080-000000000-00000

Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11598080-000000000-00000

Genomic organization, exact localization, and tissue expression of the human CD26 (dipeptidyl peptidase IV) gene

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11598080-000000000-00000

Therapeutic strategies based on glucagon-like peptide 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11598080-000000000-00000

The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11598080-000000000-00000

Pharmacokinetics of dipeptidylpeptidase-4 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11598080-000000000-00000

Pharmacology of dipeptidyl peptidase-4 inhibitors: similarities and differences.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11598080-000000000-00000

Vildagliptin add-on to metformin produces similar efficacy and reduced hypoglycaemic risk compared with glimepiride, with no weight gain: results from a 2-year study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11598080-000000000-00000

Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11598080-000000000-00000

Improved meal-related beta-cell function and insulin sensitivity by the dipeptidyl peptidase-IV inhibitor vildagliptin in metformin-treated patients with type 2 diabetes over 1 year

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11598080-000000000-00000

Effects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metformin.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11598080-000000000-00000

Clinical evidence and mechanistic basis for vildagliptin's action when added to metformin

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11598080-000000000-00000

Twelve-week monotherapy with the DPP-4 inhibitor vildagliptin improves glycemic control in subjects with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11598080-000000000-00000

Twelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11598080-000000000-00000

Improved glycaemic control with dipeptidyl peptidase-4 inhibition in patients with type 2 diabetes: vildagliptin (LAF237) dose response

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11598080-000000000-00000

Vildagliptin in drug-naïve patients with type 2 diabetes: a 24-week, double-blind, randomized, placebo-controlled, multiple-dose study.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11598080-000000000-00000

Comparison of vildagliptin and rosiglitazone monotherapy in patients with type 2 diabetes: a 24-week, double-blind, randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11598080-000000000-00000

Efficacy and tolerability of vildagliptin monotherapy in drug-naïve patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11598080-000000000-00000

Clinical experience with vildagliptin in the management of type 2 diabetes in a patient population ≥75 years: a pooled analysis from a database of clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11598080-000000000-00000

Efficacy and safety of vildagliptin and voglibose in Japanese patients with type 2 diabetes: a 12-week, randomized, double-blind, active-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11598080-000000000-00000

Comparison of vildagliptin and acarbose monotherapy in patients with Type 2 diabetes: a 24-week, double-blind, randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11598080-000000000-00000

Efficacy and tolerability of initial combination therapy with vildagliptin and pioglitazone compared with component monotherapy in patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11598080-000000000-00000

Vildagliptin in combination with pioglitazone improves glycaemic control in patients with type 2 diabetes failing thiazolidinedione monotherapy: a randomized, placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11598080-000000000-00000

Effects of one year treatment of vildagliptin added to pioglitazone or glimepiride in poorly controlled type 2 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11598080-000000000-00000

Effect of the novel oral dipeptidyl peptidase IV inhibitor vildagliptin on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11598080-000000000-00000

The absolute oral bioavailability and population-based pharmacokinetic modelling of a novel dipeptidylpeptidase-IV inhibitor, vildagliptin, in healthy volunteers.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11598080-000000000-00000

Paracellular drug transport across intestinal epithelia: influence of charge and induced water flux.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11598080-000000000-00000

Membrane transport of drugs in different regions of the intestinal tract of the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11598080-000000000-00000

Absorption, metabolism, and excretion of [14C]vildagliptin, a novel dipeptidyl peptidase 4 inhibitor, in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11598080-000000000-00000

Disposition of vildagliptin, a novel dipeptidyl peptidase 4 inhibitor, in rats and dogs

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11598080-000000000-00000

The role of sulphonylureas in the management of type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11598080-000000000-00000

Effects of rifampin on the pharmacokinetics and pharmacodynamics of glyburide and glipizide

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11598080-000000000-00000

Glyburide and glimepiride pharmacokinetics in subjects with different CYP2C9 genotypes

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11598080-000000000-00000

Impact of CYP2C9 amino acid polymorphisms on glyburide kinetics and on the insulin and glucose response in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11598080-000000000-00000

Diabetes, hypertension, and cardiovascular disease: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11598080-000000000-00000

Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11598080-000000000-00000

Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11598080-000000000-00000

Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11598080-000000000-00000

Patterns of antihypertensive therapy among patients with diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11598080-000000000-00000

Vildagliptin, a novel dipeptidyl peptidase IV inhibitor, has no pharmacokinetic interactions with the antihypertensive agents amlodipine, valsartan, and ramipril in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11598080-000000000-00000

Clinical pharmacokinetics of amlodipine

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11598080-000000000-00000

The angiotensin receptor antagonist valsartan: a review of the literature with a focus on clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11598080-000000000-00000

Ramipril: a review of its use in preventing cardiovascular outcomes in high-risk patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11598080-000000000-00000

Effect of ramipril on the incidence of diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11598080-000000000-00000

Clinical pharmacokinetics of ramipril

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11598080-000000000-00000

The human hepatic metabolism of simvastatin hydroxy acid is mediated primarily by CYP3A, and not CYP2D6.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11598080-000000000-00000

Evaluation of the potential for steady-state pharmacokinetic interaction between vildagliptin and simvastatin in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11598080-000000000-00000

Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11598080-000000000-00000

Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11598080-000000000-00000

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11598080-000000000-00000

Contemporary use of digoxin in the management of cardiovascular disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11598080-000000000-00000

Atrial fibrillation and its association with type 2 diabetes and hypertension in a Swedish community

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11598080-000000000-00000

Diabetes mellitus is a strong, independent risk for atrial fibrillation and flutter in addition to other cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11598080-000000000-00000

The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11598080-000000000-00000

Inhibition of P-glycoprotein-mediated drug transport: A unifying mechanism to explain the interaction between digoxin and quinidine [seecomments]

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11598080-000000000-00000

21 January 2018

Oral anticoagulant drugs

1 reference

https://api.crossref.org/works/10.2165%2F11598080-000000000-00000

Comparative pharmacokinetics of vitamin K antagonists: warfarin, phenprocoumon and acenocoumarol

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11598080-000000000-00000

Pharmacogenetics of warfarin elimination and its clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11598080-000000000-00000

Hydroxylation of warfarin by human cDNA-expressed cytochrome P-450: a role for P-4502C9 in the etiology of (S)-warfarin-drug interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11598080-000000000-00000

The effect of age, gender, and body mass index on the pharmacokinetics and pharmacodynamics of vildagliptin in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11598080-000000000-00000

Pharmacokinetics in older persons

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11598080-000000000-00000

Age-dependent changes of the kidneys: pharmacological implications

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11598080-000000000-00000

Clinical pharmacokinetic and pharmacodynamic considerations in patients with liver disease. An update

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11598080-000000000-00000

Effects of liver disease on pharmacokinetics. An update

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11598080-000000000-00000

Hepatic disease and drug pharmacokinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11598080-000000000-00000

Pharmacokinetics and pharmacodynamics of vildagliptin in healthy Chinese volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11598080-000000000-00000

Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4-week study period in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11598080-000000000-00000

1-[[(3-hydroxy-1-adamantyl)amino]acetyl]-2-cyano-(S)-pyrrolidine: a potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitor with antihyperglycemic properties

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11598080-000000000-00000

Effects of vildagliptin twice daily vs. sitagliptin once daily on 24-hour acute glucose fluctuations

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11598080-000000000-00000

Vildagliptin, a dipeptidyl peptidase-IV inhibitor, improves model-assessed beta-cell function in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11598080-000000000-00000

Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11598080-000000000-00000

Measurements of islet function and glucose metabolism with the dipeptidyl peptidase 4 inhibitor vildagliptin in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11598080-000000000-00000

The dipeptidyl peptidase IV inhibitor vildagliptin suppresses endogenous glucose production and enhances islet function after single-dose administration in type 2 diabetic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11598080-000000000-00000

GIP as a potential therapeutic agent?

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11598080-000000000-00000

Stimulation of insulin secretion by intravenous bolus injection and continuous infusion of gastric inhibitory polypeptide in patients with type 2 diabetes and healthy control subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11598080-000000000-00000

Gastric inhibitory polypeptide and glucagon-like peptide-1 in the pathogenesis of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11598080-000000000-00000

Gastric inhibitory polypeptide (GIP) dose-dependently stimulates glucagon secretion in healthy human subjects at euglycaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11598080-000000000-00000

Effects of glucagon-like peptide-1(7-36)amide on motility and sensation of the proximal stomach in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11598080-000000000-00000

Effects of dipeptidyl peptidase-4 inhibition on gastrointestinal function, meal appearance, and glucose metabolism in type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11598080-000000000-00000

Treatment with the dipeptidyl peptidase-4 inhibitor vildagliptin improves fasting islet-cell function in subjects with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11598080-000000000-00000

Meal and oral glucose tests for assessment of beta -cell function: modeling analysis in normal subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11598080-000000000-00000

Altered homeostatic adaptation of first- and second-phase beta-cell secretion in the offspring of patients with type 2 diabetes: studies with a minimal model to assess beta-cell function

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11598080-000000000-00000

Characterization of the influence of vildagliptin on model-assessed -cell function in patients with type 2 diabetes and mild hyperglycemia

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11598080-000000000-00000

Evidence that vildagliptin attenuates deterioration of glycaemic control during 2-year treatment of patients with type 2 diabetes and mild hyperglycaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11598080-000000000-00000

Effect of vildagliptin on glucagon concentration during meals in patients with type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11598080-000000000-00000

Abnormal alpha-cell function in diabetes. Response to carbohydrate and protein ingestion.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11598080-000000000-00000

Immunoreactive glucagon (IRG) responses to intravenous glucose in prediabetes and diabetes among Pima Indians and normal Caucasians

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11598080-000000000-00000

Abnormal response of pancreatic glucagon to glycemic changes in diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11598080-000000000-00000

Vildagliptin enhances islet responsiveness to both hyper- and hypoglycemia in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11598080-000000000-00000

Subcutaneous Injection of the Incretin Hormone Glucagon-Like Peptide 1 Abolishes Postprandial Glycemia in NIDDM

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11598080-000000000-00000

Pharmacokinetics and Pharmacodynamics of Vildagliptin??in??Patients?? with Type??2??Diabetes??Mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11598080-000000000-00000

Pharmacodynamics of Vildagliptin in Patients With Type 2 Diabetes During OGTT

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11598080-000000000-00000

Transport of digoxin by human P-glycoprotein expressed in a porcine kidney epithelial cell line (LLC-PK1).

21 January 2018

1 reference

12 December 2020

Concomitant use of cytochrome P450 3A4 inhibitors and simvastatin

1 reference

12 December 2020

Evaluation of pharmacokinetic interactions between vildagliptin and digoxin in healthy volunteers

1 reference

12 December 2020

Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers

1 reference

12 December 2020

GLP-1 slows solid gastric emptying and inhibits insulin, glucagon, and PYY release in humans

1 reference

12 December 2020

A review of enzyme induction of warfarin metabolism with recommendations for patient management

1 reference

12 December 2020

Pioglitazone is metabolised by CYP2C8 and CYP3A4 in vitro: potential for interactions with CYP2C8 inhibitors

1 reference

12 December 2020

Safety and efficacy of vildagliptin versus placebo in patients with type 2 diabetes and moderate or severe renal impairment: a prospective 24-week randomized placebo-controlled trial

1 reference

12 December 2020

Evaluation of pharmacokinetic and pharmacodynamic interaction between the dipeptidyl peptidase IV inhibitor vildagliptin, glyburide and pioglitazone in patients with Type 2 diabetes.

1 reference

12 December 2020

Cimetidine absorption and elimination in rat small intestine

1 reference

12 December 2020

Diabetes mellitus and atrial fibrillation: perspectives on epidemiological and pathophysiological links.

1 reference

12 December 2020

In vitro metabolism of simvastatin in humans [SBT]identification of metabolizing enzymes and effect of the drug on hepatic P450s

1 reference

12 December 2020

Warfarin-fluconazole. II. A metabolically based drug interaction: in vivo studies

1 reference

12 December 2020

Comparison of peripheral glucose uptake after oral glucose loading and a mixed meal

1 reference

12 December 2020

Pharmacokinetics and pharmacodynamics of vildagliptin in Japanese patients with type 2 diabetes.

1 reference

12 December 2020

Metabolic disposition studies on simvastatin, a cholesterol-lowering prodrug

1 reference

12 December 2020

Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trials

1 reference

12 December 2020

Mechanisms of the stereoselective interaction between miconazole and racemic warfarin in human subjects

1 reference

12 December 2020

Dose proportionality and the effect of food on vildagliptin, a novel dipeptidyl peptidase IV inhibitor, in healthy volunteers

1 reference

12 December 2020

Study of the pharmacokinetic interaction of vildagliptin and metformin in patients with type 2 diabetes

1 reference

12 December 2020

Drug interactions with warfarin

1 reference

12 December 2020

Both Subcutaneously and Intravenously Administered Glucagon-Like Peptide I Are Rapidly Degraded From the NH2-Terminus in Type II Diabetic Patients and in Healthy Subjects

1 reference

12 December 2020

The influence of hepatic impairment on the pharmacokinetics of the dipeptidyl peptidase IV (DPP-4) inhibitor vildagliptin

1 reference

12 December 2020

Effect of GLP-1 on gastric volume, emptying, maximum volume ingested, and postprandial symptoms in humans

1 reference

12 December 2020

10.2165/11598080-000000000-00000

Identifiers

DOI

1 reference

PubMed ID

22339447

Dimensions Publication ID

26 August 2017

0 references

1 reference

PubMed ID

22339447